Urinary retention is the inability to empty the bladder. With chronic urinary retention, you may be able to urinate, but you have trouble starting a stream or emptying your bladder completely. You may urinate frequently; you may feel an urgent need to urinate but have little success when you get to the toilet; or you may feel you still have to go after you’ve finished urinating. With acute urinary retention, you can’t urinate at all, even though you have a full bladder. Acute urinary retention is a medical emergency requiring prompt action. Chronic urinary retention may not seem life threatening, but it can lead to serious problems and should also receive attention from a health professional.
Comparing five-year results of Medtronic TUNA® Therapy (transurethral needle ablation) to surgery for 121 men in their mid-60s with lower urinary tract symptoms caused by an enlarged prostate, a team of urologists found that “for appropriately selected patients with bothersome voiding symptoms, TUNA is an attractive treatment option.”
The incidence of sexual dysfunction in patients suffering from Benign Prostatic Hyperplasia (BPH) -- or enlarged prostate -- is nearly twice as high as treating physicians believe shows a new survey from the American Foundation for Urologic Diseases (AFUD) presented today at the American Urological Association annual meeting.
The results of the ALFAUR (ALFuzosin in Acute Urinary Retention) study, announced today at the XIXth European Association of Urology (EAU) Congress in Vienna, Austria, indicate that the uroselective alpha1-blocker alfuzosin 10 mg once daily (OD) may have a beneficial effect in the management of male patients suffering from acute urinary retention (AUR), a sudden inability to pass urine that results in a painful distension of the bladder, requires immediate management with urethral catheterization and could necessitate surgical intervention.